administration. Lung s wer e excised from animals untre ated and on days 0 (without HCI instillation ), 1,3, and 7 after instillation of HC!. Northern blot analysis and in situ hybridi zation for SP-A, SP-B, SP-C , SP-D , and CC-lO mRNAs were perform ed .
The liver represents an important target organ for gen e therapy becaus e there are a large number of hepatodeficiencies and acqui red infection s that in theo ry are curable. Th e hep atocyte, the major cell type in the tissue, is able to secret e large quantities of serum proteins , and the liver, unlike most organs, is able to regenerate to its original mass.
A gene transfer vecto r receiving wide att enti on is based on the human ade novirus that represents over 40 different serotyp es and are 36-kilobase (kb) double-stranded DNA viruses. Th e molecular stru cture and regulation of this virus have been well studi ed over the years. The virus was first used in the 1980s for introducing foreign gen es into cells. More recently , the E1a region of the virus that expresses transcriptional factors necessary to induce appropriate synthe sis of the more than 70 viral proteins need ed for viral replication has been removed, suppli ed in trans, and replaced with therapeutic gene sequ en ces. Over the past 6 years, multiple studi es performed by differ ent laborat ories have demon strated that recombi- ' From the Division of Med ical Ge netics, Univers ity of Wash ington , Seattle. nant adenovirus vectors hold promis e for use in gene transfer into a number of differ ent tissues as a means of performing gene therapy for genetic and acquired disorders. Th e advantages in using these vectors are the result of the follo"' Ting: (1) the wide variety of cell types that can be tran sduc ed in vitro and in vivo; (2) the ability to concentrate the vector to high titers of up to 10 12 plaqu eforming units/mL ; and (3) the fact that gene transfer occurs without the requirement of cellular division and the viral genome does not integrate into the host chromosome. The distribution of vector DNA in tissues is dep end ent on the rout e of administration. Most of the virus is taken up by hepatocytes when given by peripheral or portal vein infusion.' Th e vector can also be delivered to the lungs, muscle, endothelial cells, and the CNS with relatively high efficiency>" The excite ment of using these vectors for gen e ther apy was temp ered by a relatively short ter m of gene expression and the inability to transduce cells a second time in animal models. Int erestingly, although the vector DNA does not integrate into the cell, vectors admini stered to mice deficient in antigen-dependent immunity have long-term persistence of over 10 months in some studies. Additionally, functional B-and T-cell deficiency allows for repeated transduction."
Data from several groups using murine models of gen e th erapy direct ed toward th e lun g and th e liver have helped to elucida te th e nature of th e immune responses limiting adenov iral-m ediated gene th er apy.7.11 In sum, it appears that T-cell-dep endent, antigen-specific immunity limits the duration of transduc ed gen e expression followin g inoculation of naive animals, and largely pr event s gen e exp ression following secondary administration. Using mice with selec tive absence of CD8 or CD4 T ce lls or B cells, it appe ars th at (1) CD 8 T cells playa predominant role in limiting th e duration of gene expression by eliminating tr ansduced cells or th e tr ansduced gene product, whereas CD4 T cells play a cont ributory role , and (2) CD4 T cell s, by pr oviding help to B cells, facilitate th e production of neutralizing antibody in th e se rum and th e airways, which pr ecludes ge ne expression following secondary administration of th e same or relat ed ade noviral vectors. Based on a number of differ ent studies , it appears th at the C D8 -medi at ed immune respo nse is largely directed to newly synthesized viral gene products produced at low levels in th e cells of animals receiving th e first-g en eration viru ses .
Th ere are two major approaches that will be need ed to combat the immunologic respon se to the vector. One method is to produc e a less antigenic vector. Advanced gene ration adenovirus vectors delet ed for specific portions of the viral genome have be en produced in different laboratori es and are currently being tested in a variety of animal models. To date, some of these vectors include second-generation adenoviral vectors that conta in E ll E2a 12 . L5 or E lIE4 16 ,17 deletions . Although it is not clear whether such vectors will persist longer, they appear to be less toxic than first-generation vectors.!" New technical advances are bein g used to produce a vector delet ed of all viral genes. 19 ,20 Addition ally, attenuation of the immune response would facilitate more prolonged gene expression and minimize inflammati on after initial vector administration and will most certainly be necessary if secondary gene transduction is to be achieved .
Immunomodulatory regimens used as adjunct ther apy may be necessary to achieve long-term and/or repea t gene transfer. Recombi nant ade noviral vecto rs containi ng the canine factor IX complementary D NA we re infused into the port al vasculature of dogs with canine hemophilia 8 resulting in therap euti c levels of factor IX within hours and thr ee times the norm al concentration of 11 J. . l-glmL within days.2:J Concomitant with the rise in plasma factor IX concentrations, coagulation parameters were restored to normal. Similarly, therap euti c serum concentrations of hum an <XI-antitrypsin wer e obtain ed in normal mice infused with a similar recombinant adenovirus . Interestingly, discrepan cy with the persistence of gene expression was obtained between the two speci es. Th e dogs had a two to thr ee log falloff in gene expression within the first several weeks, while the mice continued to persist with high levels of hum an <X1-antitl)'P sin24 or canine factor IX.2. 1 As it turns out , the persistence in mice is obtained only in specific mouse strains, the biological basis for which is not known.' \Ve have referred to this as long-or short-term expressing stra ins. Introduction of the sever e combined immunodeficient mutatio n (functionally deficient in Tand B-cell function ) results in convers ion of a short-term expressing stra in into a long-ter m expressing line. Furthermore, secondary gene transfer, which is blocked in all mouse strains due to a humo ral immune response, is possible in severe combined immun odeficient mice. As discussed in the introduction, it is now apparent that the host immune response is respon sible for the elimination of transdu ced hepatocytes. Thi s has led to developing a less antigenic ade noviral vector and atte mpting to interfer e with the host immune response to atte mpt to prolong aden ovirus-m ediated gene expression and administe r a second dose of vector.
NEW S T HATEGIE S FOH IMPROVED ADENOVIRAL-MEDIATED GENE TRANSFER lmmunomodulation by Blockage of Cost imulato ry Signals
To enhance gene expression, we have sought and obtained partial success in modifying the host respon se by selectively blocking the inter action s of costimulatory ligands on T lymph ocytes and antigen -prese nting cells (APC), which play an important role in the initiation of an effective, antigen-sp ecific immunologic respon se. Blockade of the costimulatory inter actions between CD28 on T cells with 137-1,-2 on APC using soluble CTLA4Ig is one such example. Mice given soluble CT LA4Ig near the tim e of hep atic gene tra nsfer with a first-generation recombinant adenovirus had persistent gene expression for > 6 months (length of expe riment), whe reas control anim als had a fall-off of gene expression within th e first 2 to 7 weeks.F Th e mechani sm by which CT LA4Ig prolonged adenovirus-mediated gene expression was investigated by studying the T-cell responses of recipient s. Pro lifer ation of splenic T cells in response to the adenovirus was evident in control anima ls that received the vector as early as day 11, but was absen t or markedly redu ced in anima ls receiving CT LA4Ig. In agreement with the in vitro splenocyte assays, T-cell infiltration into the livers of muCTLA4Ig-treated mice was minima l and similar to that seen in mice not receiving adenovirus, wher eas control mice receiving adenovirus had robust infiltration of C D3-, CD 4-, and CDS-positive cells. CT LA4Ig ther apy resulted in a marked and significant reduction of neutralizing antibodies but did not totally ablate the response.
Th e role of costimulatory ligand s in T cell-APC int eraction is not unidirectional from the APC to the T cell. Bather , activated T cells also express cell sur face prot eins that stimulate APC functions. A critical T-cell protein in this regard is the CD40 ligand. This protein is expressed primarily on activate d CD4 T cells and is critical to th eir ability to provide help for B-cell antibody respon ses by engagement of CD40 on 13 cells. 2H . 2 !l C D40 ligand on activated T cells also enhances APC function, in part by inducing or enhancing expression of the B7 pr otein s.>' Th e import ance of this ligand is und erscored by the X-linked hyper-I gM syndrome, which is the conseque nce of a genetic deficien cy in expression of a func tion C D40 ligand . Affected individuals have a profound inability to provide help to 8 cells, which results in the lack of B-cell me mory responses, and diminished overall antibody respo nses to T cell-depe ndent antigens, which are essentially limited to production of IgM isotype." In additi on , these individuals suffer from certain infections against which T-cell-, rath er than B-cell-mediated immunity appears be essential.s? In mice, ad ministration of monoclon al antibody to CD40 ligand (MRl) repro duces the defects of the gen etic immunode ficiency : it pr ofoundly inhibits antibody production (especially antibody oth er than IgJ\l) ,
blockage of both CD40 and CD28 costimulatory pathways with MRI and CTLA41g has recently been shown to improve th e engraftme nt of highly imm uno genic allografts .;l4 Further , initial results suggest that blockage of the CD40 pathway may also resu lt in prolonged adenoviral-rned iated gene expression ." Ongoing studies using both MRI and CTLA4Ig for hepatic gene transfer have been perfo rmed while prelim inary studies with gene tran sfer to th e lung are underway. Dual blockage of the CD28-B7 and CD40-CD40 ligand allows for persistent gene expression but also allows for secondary administration of virus in about 50 % of mice after the immunosuppressive effect s of the two agents are no longe r present.
This type of therapy has several pot ential advantages over cytoablative therapy: (I) it resu lts in transi ent immunosuppression ; (2) it is not cytoab lative and doe s not affect oth er cells (eg, neutrophils ) involved in innate immune responses; (3) it has minimal effect on pre existing immunity; and (4) it is unlikely to result in immunologic toleran ce to wild-type adenovirus .
Inteiferenc e With Antigen Presentation
The adenovirus E3 region poten tially encodes nine proteins, is well conserved between serotypes, and is not essential for viral repli cation.36o . 3s Four of thes e nine proteins have been characterized , and appear to function as immunoregulatory proteins.F-" Three of thes e immunoregulatory proteins (14.7k, 14.5k, and lOAk) have bee n found to prevent tumor necrosis factor-mediated cytolysis in vitro. 39 Th e four th , E3-gpI9K, has been shown to inhibit target cell lysis by activate d T lymphocyt es -" by binding and retaining these molecu les in the endoplasmic reticulum, and thus stopping the migrat ion of major histocompatibility complex (MI-IC) I alpha chain molecules to the cell surface." Decreasing cell surface levels of MHC I and th e expression of proteins that interfere with tumor necrosis facto r are two mechanisms th at wild-type adenovirus utilizes in evading th e host immune response ."
An Ela-deleted adenovirus vector constitutively expressing native ade novirus E3-gp19K (AdRSV-gp I9K) was constructe d to determine wheth er E3 -gp I9K)-medi ated interference with anti gen presentation would result in pro longed tr ansgene expression in vivo. Cultured fibroblasts infected with AdRSV-gp I9K produced a native size gp19K that was proved to be funct ionally active by its ability to decrease the cell surface levels of MHC 1. The con genic mous e strains Balb/b (I-I _2 h MHC I with high gp19K affinity), Balb/k (H _2 k MHC I with no gp19K affinity), and Balb/c (H _2 d MHC I with mod erate gp19K affinity) wer e chosen for in vivo expe rime nts becaus e of th eir range of gp19K affinities. Following transduction of mice from each str ain with AdRSV-gp19K and AeVRSVhAAT (a reporter adenovirus ), or an irrelevant control adenovirus and Ad/ RSV-hAAT, the level and duration of serum hAAT protein were unrelated to gp19 K protein expression. Evaluation of MIlC I abundance on hepatocytes following in viw transduction demonstrated that recom binant adenovirus rapidly incr eased the abundance of surface MHC I molecules on hepa tocytes , and surface MHC I molecul es were reduced earli er and to a great er extent following wild-type adenovirus infection compared with hepatocytes transduced with control or AdRSVgp19K recombinant adenovirus . This difference in surfac e MHC I downregu lation may be related to the different promoters (RSV-LTR vs the native E3 promoter ). Thus , exogenous E3-gp19k expression app ears to be too little too late for achieving the desired biological effect. Perhaps a stronger promoter and/or th e inclusion of oth er gen es that downregulate MHC class I by diffe rent mechanisms such as th e herpes virus I CP47 gene 42 ,43and/or other adenoviral E3 gen e products that help evade th e host immune response will result in greater success when add ed to recombinant vecto rs.
Less Antigenic Vectors
The second approach is to make a less antigenic adenovirus by deletion of the remai ning genes in the vector. Because of th e num erous and high-level transcription of genes req uired for replication of the vector, it has not been possible to produce a packaging cell line similar to those obtained for recombinant retroviral vectors . The prokaryotic ere/lox recombination system was adapted to generate recombinant ade noviruses with extended deletions in the viral genome to minimi ze expression of immunogenic and/or cytotoxic viral protein s."? As an example , an adenovirus with a 25-kb deletion , excluding E l , E2 , E3 , and late gene expression with viral titers similar to th at achieved with first-generation vectors and < 0.5% contamination with Ef -deficient virus was produced . Gen e transfer was similar in HeLa, mouse hepatoma, and primary mouse hep atocytes in vitro and in vivo as det ermined by measuring reporter gene expression and DNA tran sfer. However , transgene expression and deleted viral DNA concentrations wer e not stable and declin ed to und etectable levels muc h more rapid ly than those found for first-generation vectors . Th e IV admini stration of delet ed vectors in mice result ed in no he patocellular injury relative to first-gen eration vecto rs. Th e mechanism for stability of first-gen eration adenovirus vectors (E l a-deleted ) appeared to be linked in part to their ability to replicate in transduced cells in vivo and in vitro. Furthermore, th e deleted vectors were stabilized in th e presence of undeleted first-generation adenoviral vectors . Th us, th e shortened 9-kb deleted vector constructed in this laboratory is able to transduce DNA at an equal efficiency as firstgeneration vector but is unab le to persist possibly due to its inability to replicate. Further studi es are required to determine th e mechanism (s) of vecto r DNA stability, including which genes may be required. Placement of these genes may ce rt ainly resu lt in some immune response, and the viral particl e itself should be sufficient to lead to a humoral immune response inhibiting secondary delivery of the same vector.
CONCLUSIONS
Th e theoretical ability to use recombinant adenovirus vectors as an efficient means of successfully performing gene tr ansfer in humans has been hamper ed by the resulting imm unologic respons e against the vector. Althou gh modifications of the vector are simple in concept, they are plagued with techn ical difficulties that have just begun to be overcome . Thus, with the impro vem ents in the vector and the possibility of using adjun ct immunomodul ation regimens, the next few years will be impo rtant for det ermining the suitability of these vecto rs for gene therapy relatin g to disorders requiring short-te rm, longterm, and/ or rep eat gene transfer for clinical gene therapy. the net negative cha rge of MUCl.4 Althou gh th er e is evide nce that this mu cin alters cell-matrix and cell-cell int eractions in various culture syste rn s.v" its spe cific fun ction in hu man airway remains unkn own. Because of th e unique physical prop er ties of MUC 1, we hypoth esized that MUCI may reduce the efficiency of gene tra nsfer with recombinant adenoviruses. Using culture d hu man bronch ial epithe lial (H BE) cells, Madin Darby Canine Kidney (MDC K) cells th at were transdu ced to express hu man M UCl, and a xenogra ft model of human airway, we demonstr ate that sialoglycoconju gates such as MUC I impair adenovirus-me diated gene transfer, and that enzymatic re moval of sialic acid from epithelial cells in vitro and ill vivo increases th e efficiency of gene transfer by this vector.
METHODS AN D R E SULTS
Sero types 5 and 2, El -deleted reco mbinant adenoviruses containing the Escherichia coli LacZ reporter gene driven by the cytomegalovi ru s pro moter (AdCMV[acZ and Ad2 fjgal2) were constructed, purifi ed , and assayed for th e number of plaqu e-forming units per milliliter as pr eviously described.t-" Colocalizatio n of M VC l and fj-galactosidase exp ression in HBE cells was perform ed to beg in to address a potential influence of MUCl on adenovirusmedi ated gene transfer. Double imm unofluo rescence staining of HBE cells followin g recom binant ade noviru s infection revealed significant differences in the percentage of cells exp ressing fj-galactosidase in relation to MUCl expression. At multiplicities of infection of app roximately 100 and 1,000, fj-galactosidase expression in MUClpositive cells was approximately fivefold less th an in those that did not exp ress this mucin. T he lower transgene exp ression by MUC I -positive HB E cells suggested that MUC } is eithe r a barrier or a phen otypic marker of cells that are relatively refractory to adenovirus -mediate d gene transfer.
To fur ther evaluate the effects of MU CI on gene transfe r by recombinant aden ovirus, MD CK I cells were tran sduced with a retrovi ral vector encoding a complementary DN A for human MUCl. MUCl-expressing cells were selecte d by FACScan (Becton Dickinson , San Jose, Calif) analysis, and two clones of positive cells were found by Western blot ana lysis to express a MUCI th at contained approximately 4 (MDC Kv2) or 18 (MD C Kv3) internal tand em repeats. MD CK cells (designated MD -C Kvl ) that did not exp ress hu man MUCI by flow cyto metry serve d as control cells. Th ese ce ll lines were infected with recombinant adenovirus, and lacZ exp ression was quantitated by X-gal staining. Th e percentage of lacZexp ressing control MDC Kvl cells at a multiplicity of infection of 100 was app roximately eightfold, and at a multiplicity of infection of 1,000, threefold , higher than the MD C Kv2 and MD CKv3 cells.
To dete rmine whether sialic acid residu es on MUCI and othe r apical membrane glycoconjugates alter the efficie ncy of gene transfer, BB E and Ivl DC K cells were treated with neuraminidase prior to or afte r incu bation with recomb inant adenovirus. As sum marized in Table 1 , th e efficiency of LacZ gene tra nsfer to BBE cells in-
